Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis

Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis

Abstract Objective To investigate the efficacy and safety of docetaxel chemotherapy combined with androgen-deprivation therapy for patients with high-volume disease metastatic hormone-sensitive prostate cancer. Methods 153 cases of high-volume disease metastatic hormone-sensitive prostate cancer in...

Bibliografske podrobnosti
Main Authors:	Zhuifeng Guo, Xuwei Lu, Fan Yang, Liang Qin, Ning Yang, Jiawen Wu, Hang Wang
Format:	Article
Jezik:	English
Izdano:	BMC 2022-08-01
Serija:	European Journal of Medical Research
Teme:	Prostate cancer High-volume disease Metastatic Hormone-sensitive Docetaxel Androgen-deprivation therapy
Online dostop:	https://doi.org/10.1186/s40001-022-00773-1

Podobne knjige/članki

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
od: Hu L, et al.
Izdano: (2020-06-01)

Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
od: Kenichi Hata, et al.
Izdano: (2022-11-01)

Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
od: Whi-An Kwon, et al.
Izdano: (2019-05-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
od: İlkay Gültürk, et al.
Izdano: (2022-11-01)

Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer
od: S. V. Popov
Izdano: (2019-12-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
od: Yue Wang, et al.
Izdano: (2017-01-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
od: Fakhri Rahman, et al.
Izdano: (2017-04-01)

Choice of treatment options for metastatic hormone-sensitive prostate cancer
od: R. A. Gafanov, et al.
Izdano: (2020-12-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
od: Jian-Ri Li, et al.
Izdano: (2017-11-01)

POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER
od: A. A. GRITSKEVICH, et al.
Izdano: (2017-06-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
od: Kai-Fu Yang, et al.
Izdano: (2015-12-01)

Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta
od: Emilio Jesús Alegre del Rey, et al.
Izdano: (2017-07-01)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
od: Ietsen de Groot, et al.
Izdano: (2021-11-01)

Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world
od: Yutong Lu, et al.
Izdano: (2024-04-01)

Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran
od: Mina Tajvidi, et al.
Izdano: (2017-01-01)

Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
od: Leandro Blas, et al.
Izdano: (2022-01-01)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
od: Kyungchan Min, et al.
Izdano: (2020-04-01)

External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004
od: R Miralbell, et al.
Izdano: (2009-09-01)

Clinical characteristics and survival of patients with de novo metastatic prostate cancer treated with androgen deprivation therapy and taxane-based chemotherapy in Uganda: a retrospective study
od: Alex Bakenga, et al.
Izdano: (2024-11-01)

Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy
od: Shintaro Narita, et al.
Izdano: (2019-11-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
od: I. G. Rusakov, et al.
Izdano: (2020-12-01)

Successive xanthogranulomatous prostatitis after complete remission of metastatic prostate adenocarcinoma: An extremely rare case report with review of literatures
od: Che-Hsueh Yang, et al.
Izdano: (2020-07-01)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
od: Francesco Fiorica, et al.
Izdano: (2022-12-01)

Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients
od: LIU Sanhe, et al.
Izdano: (2019-06-01)

Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
od: Dong Jin Park, et al.
Izdano: (2024-07-01)

Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer
od: Tore Bach-Gansmo, et al.
Izdano: (2022-06-01)

Treatment patterns in hormone-sensitive metastatic prostate cancer: data from a referral hospital in Bogota, real-world evidence study
od: Juliana Arenas-Hoyos, et al.
Izdano: (2024-07-01)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
od: Giuseppe Di Lorenzo, et al.
Izdano: (2022-03-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
od: S. V. Mishugin, et al.
Izdano: (2017-11-01)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
od: Judith Passildas‐Jahanmohan, et al.
Izdano: (2021-04-01)

Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score
od: Heba Taha, et al.
Izdano: (2022-10-01)

Incidence of prostate cancer in transgender women undergoing androgen deprivation therapy: A review
od: Saurabh Tyagi, et al.
Izdano: (2023-01-01)

Relationship between Androgen Deprivation Therapy and Abdominal Adipose Tissue
od: Federico Greco, et al.
Izdano: (2022-12-01)

Current Clinical Aspects of Androgen Deprivation Therapy for Locally Advanced and Metastatic Prostate Cancer: A Scoping Review for Urologists and Medical Providers
od: Kassab JG, et al.
Izdano: (2024-09-01)

AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
od: Mads Dochedahl Winther, et al.
Izdano: (2020-07-01)

Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
od: Thiago S. Lima, et al.
Izdano: (2022-06-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
od: Yutaka Yamamoto, et al.
Izdano: (2024-03-01)

The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma
od: Niraj Kumar, et al.
Izdano: (2022-06-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
od: DUAN Liqun, et al.
Izdano: (2019-09-01)

Weekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer
od: Hyeong Dong Yuk, et al.
Izdano: (2024-12-01)